PMID- 27535028
OWN - NLM
STAT- MEDLINE
DCOM- 20171127
LR  - 20210504
IS  - 1365-2060 (Electronic)
IS  - 0785-3890 (Linking)
VI  - 49
IP  - 1
DP  - 2017 Feb
TI  - Effects of antidiabetic drugs on the incidence of macrovascular complications and 
      mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose 
      co-transporter 2 inhibitors.
PG  - 51-62
LID - 10.1080/07853890.2016.1226514 [doi]
AB  - Elevated hemoglobin A(1c) (HbA(1c)) values correlate with microvascular and 
      macrovascular complications. Thus, patients with type 2 diabetes mellitus (T2DM) 
      are at an increased risk of developing macrovascular events. Treatment of T2DM 
      should be based on a multifactorial approach because of its evidence regarding 
      reduction of macrovascular complications and mortality in T2DM. It is well known 
      that intensive glucose control reduces the risk of microvascular complications in 
      T2DM, but the effects of antidiabetic drugs on macrovascular complications and 
      mortality in T2DM are less clear. The results of recent trials have demonstrated 
      clear evidence that empagliflozin and liraglutide reduce cardiovascular (CV) and 
      all-cause mortality in T2DM, an effect that is absent in other members of 
      antidiabetic drugs. Empagliflozin is a member of a novel class of antidiabetic 
      drugs, the sodium-glucose co-transporter 2 (SGLT2) inhibitors. Two ongoing 
      randomized clinical trials involving other SGLT2 inhibitors, canagliflozin and 
      dapagliflozin, will provide additional evidence of the beneficial effects of 
      SGLT2 inhibitors in T2DM population. The aim of this paper is to systematically 
      present the latest evidence regarding the usage of antidiabetic drugs, and the 
      reduction of macrovascular complications and mortality. A special emphasis is put 
      on the novel class of antidiabetic drugs, of SGLT2 inhibitors. Key messages 
      Macrovascular complications and mortality are best clinical trial endpoints for 
      evaluating the efficacy of antidiabetic drugs. The first antidiabetic drug that 
      demonstrated a reduction in mortality in the treatment of type 2 diabetes 
      mellitus (T2DM) was empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) 
      inhibitor. SGLT2 inhibitors are novel class of antidiabetic drugs that play a 
      promising role in the treatment of T2DM.
FAU - Rahelic, Dario
AU  - Rahelic D
AD  - a Department of Endocrinology, Diabetes and Metabolic Disorders , Clinical 
      Hospital Dubrava , Zagreb , Croatia.
FAU - Javor, Eugen
AU  - Javor E
AD  - b Pharmacy Department , University Hospital Sisters of Mercy , Zagreb , Croatia.
FAU - Lucijanic, Tomo
AU  - Lucijanic T
AD  - a Department of Endocrinology, Diabetes and Metabolic Disorders , Clinical 
      Hospital Dubrava , Zagreb , Croatia.
FAU - Skelin, Marko
AU  - Skelin M
AD  - c Pharmacy Department , General Hospital Sibenik , Sibenik , Croatia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160922
PL  - England
TA  - Ann Med
JT  - Annals of medicine
JID - 8906388
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Blood Glucose)
RN  - 0 (Glucosides)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 0SAC974Z85 (Canagliflozin)
RN  - 1ULL0QJ8UC (dapagliflozin)
RN  - HDC1R2M35U (empagliflozin)
SB  - IM
MH  - Benzhydryl Compounds/therapeutic use
MH  - Blood Glucose/drug effects
MH  - Canagliflozin/therapeutic use
MH  - Diabetes Mellitus, Type 2/*complications/drug therapy/mortality
MH  - Diabetic Angiopathies/*drug therapy/mortality/prevention & control
MH  - Glucosides/therapeutic use
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - *Incidence
MH  - Randomized Controlled Trials as Topic
MH  - Sodium-Glucose Transporter 2/metabolism
MH  - *Sodium-Glucose Transporter 2 Inhibitors
OTO - NOTNLM
OT  - Type 2 diabetes mellitus
OT  - antidiabetic drugs
OT  - macrovascular complications
OT  - mortality
OT  - sodium-glucose co-transporter 2 inhibitors
EDAT- 2016/08/19 06:00
MHDA- 2017/11/29 06:00
CRDT- 2016/08/19 06:00
PHST- 2016/08/19 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
PHST- 2016/08/19 06:00 [entrez]
AID - 10.1080/07853890.2016.1226514 [doi]
PST - ppublish
SO  - Ann Med. 2017 Feb;49(1):51-62. doi: 10.1080/07853890.2016.1226514. Epub 2016 Sep 
      22.